LoRezTrader (@loreztrader) 's Twitter Profile
LoRezTrader

@loreztrader

LT B&H investor taking occasional swings. Focus on disruptive, transformational bets w/ potential to 5-10x+. Med/biotech, SaaS, e-comm, space, crypto/web 3.0

ID: 1268056293241245696

calendar_today03-06-2020 05:46:30

11,11K Tweet

2,2K Takipçi

494 Takip Edilen

Children's Hospital (@childrensphila) 's Twitter Profile Photo

CHOP & Penn Medicine have delivered the first-ever personalized gene editing therapy for a patient with CPS1 deficiency, marking a major milestone in the application of CRISPR-based treatments. Learn more about KJ & the future of personalized medicine: ms.spr.ly/6015SZLAx.

Kab X (@kabraxfx) 's Twitter Profile Photo

$TMDX Reposting a video from LinkedIn of a live pumping heart being transported in a $TMDX OCS system via plane. ✈️❤️🔥👼 Link to original LinkedIn post in the replies.

equityXplorer (@_equityxplorer) 's Twitter Profile Photo

$TMDX Some of my favorite quotes from Waleed at today’s conference. - Next Gen OCS Timeline “We expect that approval will be in hand sometime in late Q2, early Q3 to put us right on track to launch these clinical programs late this year as we anticipated in the beginning of

flosz 🍉 (@floszcrxl) 's Twitter Profile Photo

Full Steam Ahead: $QURE ’s On Track With Hope for Accelerated Approval of #HuntingtonsDisease Drug en.hdbuzz.net/full-steam-ahe… $QURE & $CLPT

Full Steam Ahead: $QURE ’s On Track With Hope for Accelerated Approval of #HuntingtonsDisease Drug

en.hdbuzz.net/full-steam-ahe… $QURE & $CLPT
BioSpace (@biospace) 's Twitter Profile Photo

The FDA plans to “rapidly make available” rare disease drugs and make use of surrogate endpoints to get promising medicines to patients before they clear the traditional efficacy bar for authorization, Prasad said Tuesday. #fda #raredisease #biospace hubs.li/Q03qF7nP0

ib (@indian_bronson) 's Twitter Profile Photo

Almost all who can afford it will pick among IVF embryos to give themselves the greatest chance at having and their children the greatest chance at being the best looking, tallest, smartest, healthiest children possible. In two generations, they'll be a highly distinct people.

Almost all who can afford it will pick among IVF embryos to give themselves the greatest chance at having and their children the greatest chance at being the best looking, tallest, smartest, healthiest children possible.

In two generations, they'll be a highly distinct people.
Children's Hospital (@childrensphila) 's Twitter Profile Photo

A few weeks ago we introduced you to KJ, who made medical history as the first patient to receive a personalized gene editing therapy. After almost a year at CHOP, KJ is now at home with his family. 🎓 Tune in to NBC's TODAY tomorrow morning to hear from his family!

Tesla Owners Silicon Valley (@teslaownerssv) 's Twitter Profile Photo

If you ever wanted to know what the process is like to receive a Neuralink implant, Brad Smith (aka Bradford G Smith (Brad)) shares his experience with us! Incredible that the process only took a few hours, and in the future will be as seamless as LASIK!

LoRezTrader (@loreztrader) 's Twitter Profile Photo

"NMP implementation was assoc. w/ significantly shorter liver transplant waitlist times & reduced hospital stays, w/o compromising short-term survival outcomes Median waitlist times - 309d pre-NMP to 48d post-NMP. NMP group had a 2d shorter hospital stay than the non-NMP"

Shay Boloor (@stocksavvyshay) 's Twitter Profile Photo

15 years ago, $NVDA CEO laid out his CUDA vision -- the stock was $0.20 split-adjusted. Today, CUDA powers everything from LLMs to robotics & quantum simulation -- a reminder that backing visionary founders early can lead to life-changing returns.

BowTiedBiotech 🧪🔬🧬 (@bowtiedbiotech) 's Twitter Profile Photo

🧬 Cell & Gene Therapies: High Risk or High Reward? Tufts just released one of the best datasets comparing CGT programs to traditional drugs. Across every phase, CGTs outperform. Some are 3.5x more likely to get approved. Here’s what the numbers tell us 🧵👇🏼

🧬 Cell & Gene Therapies: High Risk or High Reward?

Tufts just released one of the best datasets comparing CGT programs to traditional drugs.

Across every phase, CGTs outperform.

Some are 3.5x more likely to get approved.

Here’s what the numbers tell us 
🧵👇🏼
Leonardo V. Riella (@lvriella) 's Twitter Profile Photo

I was honored to host the inaugural Richard Slayman Clinical #Xenotransplantation Workshop Mass General Mass General Transplant Mass General Brigham Nephrology honoring the world’s first recipient of a gene-edited pig kidney🧬🐷140+ experts from academia,biotech &reg agencies joined to shape the future Xeno

I was honored to host the inaugural Richard Slayman Clinical #Xenotransplantation Workshop <a href="/MassGeneral/">Mass General</a> <a href="/mgh_transplant/">Mass General Transplant</a> <a href="/MGBKidneys/">Mass General Brigham Nephrology</a> honoring the world’s first recipient of a gene-edited pig kidney🧬🐷140+ experts from academia,biotech &amp;reg agencies joined to shape the future Xeno
Samuel Hume (@drsamuelbhume) 's Twitter Profile Photo

Top 5 advances in medicine in May (🧵) 1. A record-breaking genetic therapy This bespoke CRISPR therapy was tailored for one patient's mutation, breaking two records: the first personalised gene editing, and (possibly) the fastest a medicine's ever been produced There's a

Top 5 advances in medicine in May (🧵)

1. A record-breaking genetic therapy

This bespoke CRISPR therapy was tailored for one patient's mutation, breaking two records: the first personalised gene editing, and (possibly) the fastest a medicine's ever been produced

There's a